

SUPPLEMENTARY MATERIALS


Supplementary Table 1. Nucleotide sequences of primers of miR-34b for BSP.

Gene	Primer sequence(5' to 3')
Mmu-miR-34b	Sense: GTTTTAGATTTGGGTTTGGGAAGT Antisense: CAATAAAATTAATAATTATCAACACC
Has-miR-34b	Sense: AATGAGGGAGTGGAGGAGTTT Antisense: ACCCCAAACCCTAAAACCTAACT


Supplementary Table 2. Characteristics of the patients.

	Normal	ESRD
Age (years)	26.35 ± 3.235	43.42 ± 3.25
Genders	Male: 4 Female: 1	Male: 3 Female: 2
Cre (umol/l)	56.35 ± 2.726	1098 ± 134.6*
BUN (mmol/l)	5.631 ± 0.456	31.2 ± 2.358*
UA (umol/l)	284.6 ± 18.46	466.2 ± 21.49*


Abbreviation: Cre: creatinine; BUN: blood urea nitrogen; UA: uric acid; *p<0.05, compared with Normal group.



Supplementary Figure 1. Immunocytochemical staining was used to identify the phenotype of VSMCs by detecting the expression of α-SMA.



Supplementary Figure 2. (A) The expression of BTG4 mRNA detected by qRT-PCR in VSMCs treated with 3.5mM Pi or 3.5mM Pi + 10 μ M 5-aza. (B) Western blot analysis showed that 5-aza could upregulate the level of BTG4 protein in VSMCs. (C) The inhibitory efficiency of siRNAs targeting DNMT3a was verified by western blot analysis. (D) BSP showed that the methylation rate of CpG sites of miR-34b DNA was significantly lower in VSMCs with 3.5mM Pi + siDNMT3a treatment than that of 3.5mM Pi + scramble siDNMT3a. N=3. The data are expressed as mean \pm SD, * p < 0.05; ** p < 0.005.



Supplementary Figure 3. Western blot analysis measured the level of ALP activity, OC secretion and Runx2 expression in arteries from SOR mice, 5/6 NTP mice and 5/6 NTP+agomiR-34b mice. N=5. SOR: sham operation; 5/6 NTP: 5/6 nephrectomy with a high-phosphate diet.